A Sustained Virologic Response Reduces Risk of All-Cause Mortality in Patients With Hepatitis C

Clinical Gastroenterology and Hepatology

Volumn 9, Issue 6, 2011, Pages

  Backus, Lisa I ^a   Boothroyd, Derek B ^a   Phillips, Barbara R ^a   Belperio, Pamela ^a   Halloran, James ^a   Mole, Larry A ^a  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

Antiviral Therapy; Efficacy; IFN; Liver Disease

Indexed keywords

PEGINTERFERON; RIBAVIRIN;

ADULT; ARTICLE; COHORT ANALYSIS; COMORBIDITY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; RISK REDUCTION; SURVIVAL TIME; SUSTAINED VIROLOGIC RESPONSE; TREATMENT RESPONSE;

EID: 79957497436     PISSN: 15423565     EISSN: 15423565     Source Type: Journal    
DOI: 10.1016/j.cgh.2011.03.004     Document Type: Article

References (24)

1. Singal A.G., Volk M.L., Jensen D., et al. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol 2010, 8:280-288.
2. Lloyd-Jones D.M., Martin D.O., Larson M.G., et al. Accuracy of death certificates for coding coronary heart disease as the cause of death. Ann Intern Med 1998, 129:1020-1026.
3. Mostafa A., Mohamed M.K., Saeed M., et al. Hepatitis C infection and clearance: impact on atherosclerosis and cardiometabolic risk factors. Gut 2010, 59:1135-1140.
4. Imazeki F., Yokosuka O., Fukai K., et al. Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study. Hepatology 2003, 38:493-502.
5. Yu M.L., Lin S.M., Chuang W.L., et al. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Antivir Ther 2006, 11:985-994.
6. Shiratori Y., Ito Y., Yokosuka O., et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 2005, 142:105-114.
7. Fernandez-Rodriguez C.M., Alonso S., Martinez S.M., et al. Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response. Am J Gastroenterol 2010, 105:2174-2176.
8. Veldt B.J., Heathcote E.J., Wedemeyer H., et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007, 147:677-684.
9. Tanaka Y., Kurbanov F., Mano S., et al. Molecular tracing of the global hepatitis C virus epidemic predicts regional patterns of hepatocellular carcinoma mortality. Gastroenterology 2006, 130:703-714.
10. Keam S.J., Cvetkovic R.S. Peginterferon-alpha-2a (40 kD) plus ribavirin: a review of its use in the management of chronic hepatitis C mono-infection. Drugs 2008, 68:1273-1317.
11. Backus L.I., Boothroyd D.B., Phillips B.R., et al. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology 2007, 46:37-47.
12. Olshansky S.J., Passaro D.J., Hershow R.C., et al. A potential decline in life expectancy in the United States in the 21st century. N Engl J Med 2005, 352:1138-1145.
13. Armstrong G.L., Wasley A., Simard E.P., et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006, 144:705-714.
14. Mole L.A., Halloran J.P., Backus L.I. Numbers for knowledge, knowledge for care. Public health matters 2007, Public Health Strategic Health Care Group, Washington, DC, 2-3.
15. Butt A.A., Wang X., Moore C.G. Effect of hepatitis C virus and its treatment on survival. Hepatology 2009, 50:387-392.
16. Backus L.I., Gavrilov S., Loomis T.P., et al. Clinical Case Registries: simultaneous local and national disease registries for population quality management. J Am Med Inform Assoc 2009, 16:775-783.
17. Martinot-Peignoux M., Christianne S., Pierre R.M., et al. Assessment of serum HCV RNA at week 12 post-treatment is as relevant as week 24 to predict SVR in patients with chronic hepatitis C treatment with pegylated interferon plus ribavirin. Hepatology 2009, 50:S118.
18. Zeuzem S., Heathcote E.J., Shiffman M.L., et al. Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C. J Hepatol 2003, 39:106-111.
19. Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16:31-41.
20. Dienstag J.L., McHutchison J.G. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006, 130:231-264.
21. Wright T.L., Yee H. VA treatment recommendations for patients with chronic hepatitis C. Federal Practitioner 2003, 20:1-33.
22. Arnold N., Sohn M., Maynard C., et al. VIReC technical report 2: VA-NDI mortality data merge project. Hines, IL: VA Information Resource Center 2006.
23. Pai J.K., Pischon T., Ma J., et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004, 351:2599-2610.
24. Haffner S.M. The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am J Cardiol 2006, 97:3A-11A.